Developer docs
API playgroundTry for free, no card

Search company profiles

Pixium Vision

Full company profile

uuid00062jp

Namestring
Pixium Vision
Legal namestring
Pixium Vision SA
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Pixium Vision SA was a French medical device company founded in Paris that developed the PRIMA retinal implant system, a wireless photovoltaic subretinal prosthesis designed to restore central vision in patients suffering from advanced dry age-related macular degeneration (AMD). The PRIMA device converts light into electrical neural signals that stimulate remaining retinal cells, bypassing damaged photoreceptors to enable patients to regain functional central vision including the ability to read letters and recognize faces. Clinical evidence from 38 participants published in The New England Journal of Medicine demonstrated measurable vision improvement in approximately 80% of subjects, positioning PRIMA as a differentiated entrant in the global visual prosthesis market projected to reach $1.049B by 2034.

The company operated as a clinical-stage medical device developer, monetizing through future commercialization of the PRIMA implant rather than current product sales. Distribution was structured around specialized ophthalmology centers and clinical trial sites given the surgical nature of subretinal implantation. Total disclosed funding across four rounds (2012-2020) reached approximately $41M, with backing from European life science investors including Sofinnova Partners, Bpifrance, Kreos Capital, Abingworth, InnoBio Fund, and Omnes Capital. Leadership included CTO Guillaume Buc, Director of Clinical Affairs Ralf Hornig, and Regulatory/Quality Director Karine Chevrie.

In 2024, Pixium Vision SA's assets — including the PRIMA technology and ongoing clinical trials — were acquired by Science Corporation (led by former Neuralink President Max Hodak). Following the acquisition, Pixium Vision SA no longer operates as an independent entity; European clinical trial sponsorship and legal manufacturing were transferred to La Science SAS, a Science Corporation affiliate. The Pixium Vision product page now redirects to Science Corporation's domain.

Short descriptiontext

Pixium Vision SA was a Paris-based clinical-stage medical device company developing the PRIMA wireless photovoltaic subretinal implant to restore central vision in patients with advanced age-related macular degeneration; acquired by Science Corporation in 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
retinal implant systems, visual prosthesis devices, subretinal prosthetics, macular degeneration treatment, bionic vision technology
Industry2 codes
PRIMARYHLAHAJAN
Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Ophthalmic Goods Manufacturing339115
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Ophthalmic Goods3851
Product category
Visual Prosthetics / Retinal Implants
Social media profiles2 records
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pixium Vision developed the PRIMA retinal implant, a wireless photovoltaic subretinal prosthetic device that restores central vision in patients with advanced dry age-related macular degeneration (AMD). The implant converts light into electrical signals transmitted via the visual cortex, enabling patients to regain abilities such as reading letters and recognizing faces. The device was originally developed in collaboration with Stanford scientists and demonstrated an 80% success rate in clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 80% of participants showed measurable vision improvement
+1 more record
Product overview1 text field

Pixium Vision developed the PRIMA retinal implant, a bionic vision system designed to restore central vision in patients with age-related macular degeneration. The company's assets, including ongoing clinical trials and the PRIMA device, were acquired by Science Corporation in 2024. The European clinical trials are sponsored by La Science SAS. The PRIMA implant works by converting light into neural signals that the brain can interpret, helping patients regain sight.

Product and service1 record
1PRIMA Retinal Implant
CategoryVisual Prosthetics / Retinal Implant
Description

The PRIMA retinal implant is a wireless bionic vision system that restores sight in patients with advanced macular degeneration by converting light into electrical signals transmitted via the visual cortex. It is designed for patients with advanced dry age-related macular degeneration (AMD) who have lost central vision and is implanted via specialized ophthalmic surgery.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
TypeOthers
Description

Science Corporation acquired Pixium Vision SA's assets including the PRIMA retinal implant technology and ongoing clinical trials in late-stage macular degeneration in 2024. Science Corporation is continuing the development and commercialization of the PRIMA device.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

GenSight Biologics develops gene therapy approaches (e.g., Lumevoq for Leber hereditary optic neuropathy) that compete with PRIMA in restoring vision in patients with retinal/optic nerve disorders, representing a non-device alternative modality in adjacent indications.

2Retina Implant AG
TypeDirect peer
Description

Retina Implant AG developed the subretinal Alpha IMS/AMS implant for retinitis pigmentosa using a photovoltaic-style approach, directly comparable to PRIMA's mechanism. Both companies are European and pioneered subretinal wireless implant architectures for blindness.

TypeEmerging player
Description

eSight develops electronic glasses that enhance functional vision for low-vision patients, including those with macular degeneration. It addresses the same patient population as PRIMA via a non-invasive wearable rather than a surgical implant.

TypeOthers
Description

Neuralink, founded by Elon Musk, develops brain-computer interface implants and shares leadership ecosystem overlap with Science Corporation (Max Hodak was Neuralink's former president). It represents an adjacent neurotechnology modality that competes for capital and talent in the implantable vision-restoration space.

5Corning Incorporated
TypeOthers
Description

Corning supplies advanced optical materials and components used across ophthalmic and medical device applications, relevant as a potential supplier of specialized optical/coating materials for next-generation retinal implants like PRIMA.

TypeEmerging player
Description

OrCam produces AI-driven wearable assistive vision devices (MyEye) for visually impaired users, offering an alternative non-invasive approach to functional vision support that competes for the same AMD/low-vision patient segment.

7Second Sight Medical Products
TypeDirect peer
Description

Second Sight developed the Argus retinal prosthesis system for retinitis pigmentosa and advanced AMD, making it the most direct historical peer to PRIMA in subretinal/epiretinal vision restoration implants. Both target restoration of functional vision in patients with profound photoreceptor loss.

TypeEmerging player
Description

Nano Retina is an Israeli emerging player developing the NR600 retinal implant for vision restoration in retinal degenerative diseases. It targets the same patient population as PRIMA with a competing miniaturized implant approach.

TypeEmerging player
Description

Bionic Vision Technologies is an Australian company developing the Phoenix bionic eye system for retinitis pigmentosa, a comparable suprachoroidal retinal prosthesis targeting the same functional vision restoration use case as PRIMA.

TypeDirect peer
Description

Science Corporation acquired Pixium Vision's PRIMA assets in 2024 and now owns and is commercializing the device through La Science SAS, making it both the acquirer and the primary entity advancing PRIMA's clinical and commercial development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pixium Vision

Visual Prosthetics / Retinal Implantspixium-vision.com

Pixium Vision SA was a Paris-based clinical-stage medical device company developing the PRIMA wireless photovoltaic subretinal implant to restore central vision in patients with advanced age-related macular degeneration; acquired by Science Corporation in 2024.

What Pixium Vision does

Pixium Vision SA was a French medical device company founded in Paris that developed the PRIMA retinal implant system, a wireless photovoltaic subretinal prosthesis designed to restore central vision in patients suffering from advanced dry age-related macular degeneration (AMD). The PRIMA device converts light into electrical neural signals that stimulate remaining retinal cells, bypassing damaged photoreceptors to enable patients to regain functional central vision including the ability to read letters and recognize faces. Clinical evidence from 38 participants published in The New England Journal of Medicine demonstrated measurable vision improvement in approximately 80% of subjects, positioning PRIMA as a differentiated entrant in the global visual prosthesis market projected to reach $1.049B by 2034.

The company operated as a clinical-stage medical device developer, monetizing through future commercialization of the PRIMA implant rather than current product sales. Distribution was structured around specialized ophthalmology centers and clinical trial sites given the surgical nature of subretinal implantation. Total disclosed funding across four rounds (2012-2020) reached approximately $41M, with backing from European life science investors including Sofinnova Partners, Bpifrance, Kreos Capital, Abingworth, InnoBio Fund, and Omnes Capital. Leadership included CTO Guillaume Buc, Director of Clinical Affairs Ralf Hornig, and Regulatory/Quality Director Karine Chevrie.

In 2024, Pixium Vision SA's assets — including the PRIMA technology and ongoing clinical trials — were acquired by Science Corporation (led by former Neuralink President Max Hodak). Following the acquisition, Pixium Vision SA no longer operates as an independent entity; European clinical trial sponsorship and legal manufacturing were transferred to La Science SAS, a Science Corporation affiliate. The Pixium Vision product page now redirects to Science Corporation's domain.

Pixium Vision firmographics

Firmographics
Name
Pixium Vision
Legal name
Pixium Vision SA
Website
https://pixium-vision.com
Company type
Private
Founded year
2014
Operating status
Acquired
Headcount range
1–10 employees
Short description
Pixium Vision SA was a Paris-based clinical-stage medical device company developing the PRIMA wireless photovoltaic subretinal implant to restore central vision in patients with advanced age-related macular degeneration; acquired by Science Corporation in 2024.
Ownership category
akta.pro rank

Pixium Vision industry classification

Industry
Product category
Visual Prosthetics / Retinal Implants
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Ophthalmic Goods Manufacturing (339115)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAN
Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Retinal implant systems
  • Visual prosthesis devices
  • Subretinal prosthetics
  • Macular degeneration treatment
  • Bionic vision technology

Where Pixium Vision is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

Pixium Vision business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Pixium Vision product offering

Product offering

Core offering

Pixium Vision developed the PRIMA retinal implant, a wireless photovoltaic subretinal prosthetic device that restores central vision in patients with advanced dry age-related macular degeneration (AMD). The implant converts light into electrical signals transmitted via the visual cortex, enabling patients to regain abilities such as reading letters and recognizing faces. The device was originally developed in collaboration with Stanford scientists and demonstrated an 80% success rate in clinical trials.

Product overview

Pixium Vision developed the PRIMA retinal implant, a bionic vision system designed to restore central vision in patients with age-related macular degeneration. The company's assets, including ongoing clinical trials and the PRIMA device, were acquired by Science Corporation in 2024. The European clinical trials are sponsored by La Science SAS. The PRIMA implant works by converting light into neural signals that the brain can interpret, helping patients regain sight.

Differentiator

Problem solved

Functional benefit

Products and services

  • PRIMA Retinal Implant The PRIMA retinal implant is a wireless bionic vision system that restores sight in patients with advanced macular degeneration by converting light into electrical signals transmitted via the visual cortex. It is designed for patients with advanced dry age-related macular degeneration (AMD) who have lost central vision and is implanted via specialized ophthalmic surgery.

Quantifiable outcome

  • 80% of participants showed measurable vision improvement
  • +1 more outcomes

Companies that use Pixium Vision

Customer profile

Segments1 record

Ideal customer profiles1 record

Pixium Vision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pixium Vision partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Science CorporationOthersScience Corporation acquired Pixium Vision SA's assets including the PRIMA retinal implant technology and ongoing clinical trials in late-stage macular degeneration in 2024. Science Corporation is continuing the development and commercialization of the PRIMA device.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Pixium Vision competitors and assessment

Company assessment

Emerging players

  • GenSight Biologics: GenSight Biologics develops gene therapy approaches (e.g., Lumevoq for Leber hereditary optic neuropathy) that compete with PRIMA in restoring vision in patients with retinal/optic nerve disorders, representing a non-device alternative modality in adjacent indications.
  • eSight Eyewear: eSight develops electronic glasses that enhance functional vision for low-vision patients, including those with macular degeneration. It addresses the same patient population as PRIMA via a non-invasive wearable rather than a surgical implant.
  • OrCam Technologies: OrCam produces AI-driven wearable assistive vision devices (MyEye) for visually impaired users, offering an alternative non-invasive approach to functional vision support that competes for the same AMD/low-vision patient segment.
  • Nano Retina: Nano Retina is an Israeli emerging player developing the NR600 retinal implant for vision restoration in retinal degenerative diseases. It targets the same patient population as PRIMA with a competing miniaturized implant approach.
  • Bionic Vision Technologies: Bionic Vision Technologies is an Australian company developing the Phoenix bionic eye system for retinitis pigmentosa, a comparable suprachoroidal retinal prosthesis targeting the same functional vision restoration use case as PRIMA.

Direct peers

  • Retina Implant AG: Retina Implant AG developed the subretinal Alpha IMS/AMS implant for retinitis pigmentosa using a photovoltaic-style approach, directly comparable to PRIMA's mechanism. Both companies are European and pioneered subretinal wireless implant architectures for blindness.
  • Second Sight Medical Products: Second Sight developed the Argus retinal prosthesis system for retinitis pigmentosa and advanced AMD, making it the most direct historical peer to PRIMA in subretinal/epiretinal vision restoration implants. Both target restoration of functional vision in patients with profound photoreceptor loss.
  • Science Corporation: Science Corporation acquired Pixium Vision's PRIMA assets in 2024 and now owns and is commercializing the device through La Science SAS, making it both the acquirer and the primary entity advancing PRIMA's clinical and commercial development.

Others

  • Neuralink: Neuralink, founded by Elon Musk, develops brain-computer interface implants and shares leadership ecosystem overlap with Science Corporation (Max Hodak was Neuralink's former president). It represents an adjacent neurotechnology modality that competes for capital and talent in the implantable vision-restoration space.
  • Corning Incorporated: Corning supplies advanced optical materials and components used across ophthalmic and medical device applications, relevant as a potential supplier of specialized optical/coating materials for next-generation retinal implants like PRIMA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Pixium Vision social profiles

Digital presence

Pixium Vision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pixium Vision leadership team

Management profile

Number of profiles

Profiles3 records

Pixium Vision funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pixium Vision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pixium Vision

What does Pixium Vision do?

Pixium Vision developed the PRIMA retinal implant, a wireless photovoltaic subretinal prosthetic device that restores central vision in patients with advanced dry age-related macular degeneration (AMD). The implant converts light into electrical signals transmitted via the visual cortex, enabling patients to regain abilities such as reading letters and recognizing faces. The device was originally developed in collaboration with Stanford scientists and demonstrated an 80% success rate in clinical trials.

Is Pixium Vision a public or private company?

Pixium Vision is a private company. It is classified as corporate owned and is currently acquired.

When was Pixium Vision founded?

Pixium Vision was founded in 2014. It employs 1 to 10 people.

Where is Pixium Vision based?

Pixium Vision is headquartered in Paris, France, in the Europe region.

Who are Pixium Vision's main competitors?

Emerging players on record are GenSight Biologics, eSight Eyewear, OrCam Technologies, Nano Retina and Bionic Vision Technologies. Direct peers are Retina Implant AG, Second Sight Medical Products and Science Corporation. Others are Neuralink and Corning Incorporated.

Does Pixium Vision have an API?

No public API is recorded for Pixium Vision.

What industry is Pixium Vision in?

Pixium Vision's product category is Visual Prosthetics / Retinal Implants. Its primary akta.pro industry code is HLAHAJAN, Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids), with a secondary code of HLAAAGAK, Ophthalmic Regeneration (cornea/retina). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Times KuwaitEurope approves PRIMA eye implant to help restore sight in blind patientsScience Corporation received European regulatory approval for its PRIMA retinal implant, which restores sight in patients with advanced age-related macular degeneration. The device also holds the FDA's Breakthrough Device designation for two rare blindness forms. Commercial rollout is expected to begin in Germany as early as September.Financial ExpressMeet Max Hodak: Ex-Neuralink veteran leading $1.5 bn startup to make Brain Computer Interfaces safeMax Hodak, former President of Neuralink and co-founder of the $1.5 billion neurotech startup Science Corporation, is preparing to implant its first biohybrid brain sensor in a human patient later this year. Science Corp's approach differs from Neuralink by using lab-grown neurons as biological bridges rather than penetrating electrodes, with the pea-sized device containing 520 recording electrodes that sit on the cortex surface. The company recently closed a $230 million Series C funding round in March 2026, bringing total funding to approximately $490 million, and acquired the PRIMA retinal implant from Pixium Vision in 2024.The GuardianExperts hail ‘remarkable’ success of electronic implant in restoring sightThe Prima electronic eye implant, a microchip device developed by Pixium Vision, has enabled 84% of trial participants with dry age-related macular degeneration to regain the ability to read letters and numbers. The successful clinical trial, involving 38 patients across sites in the UK, Germany, France, Italy, and the Netherlands, was published in the New England Journal of Medicine as a significant advancement in artificial vision technology.MIT Technology ReviewThis retina implant lets people with vision loss do a crossword puzzleScience Corporation has acquired the PRIMA vision implant from Pixium Vision, enabling patients with vision loss to achieve forms of artificial vision, including reading text. The implant, which utilizes a microelectronic chip placed under the retina and responds to signals from a camera, was purchased at a low price, facilitating Science Corporation's entry into the market with advanced technology. The company aims to further develop and market this technology in Europe and the US.Neurotechreports2024 neurotechnology industry events, Axonics, Boston Scientific, Medtronic, mergers acquisitions (M&A) venture capital funding rounds, Shai Gozani, Pixium Vision, Tether, CMS codesIn 2024, Boston Scientific completed a significant acquisition of Axonics for $3.7 billion, highlighting optimism in the neurotechnology industry. This acquisition has potentially stimulated further investment, as evidenced by recent funding rounds totaling over $300 million across various neurotech firms. Overall, the year showed more positive than negative developments in the sector, setting a hopeful tone for 2025.IEEE SpectrumBionic Eye Gets a New Lease on LifeScience, a bioelectronics startup founded by Neuralink co-founder Max Hodak, has acquired the assets of Pixium Vision to continue development of its Prima retinal implant system. The acquisition ensures continued support for existing patients and allows Science to pursue regulatory approvals in Europe while preparing for U.S. clinical trials with the FDA.Business Wire BlogScience Corporation Acquires Pixium’s PRIMA Retinal Implant, Extending and Diversifying Its Commitment to Vision Restoration Through Brain-Computer Interface TechnologyScience Corporation acquired Pixium Vision's PRIMA retinal implant, a subretinal device with a pocket computer and glasses, after Pixium's liquidation. The deal was approved by the Paris Commercial Court, with terms undisclosed. Pixium had three ongoing clinical studies, including a pivotal trial for dry AMD.GlobeNewswirePixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedingsPixium Vision's Paris Commercial Court rejected the sale plan presented by its subsidiary NeuroTech Vision on January 31, 2024, and converted receivership proceedings into judicial liquidation. The company will not resume its Euronext listing, and delisting is imminent.GlobeNewswirePostponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024Pixium Vision's Paris Commercial Court postponed its decision on the takeover offer and judicial liquidation to January 31, 2024. The company will apply for share suspension from that date. Sale proceeds will not fully reimburse shareholders given the offer price and indebtedness.